SC0062

Asset

Blocks endothelin A receptors to reduce endothelin-mediated renal injury.

Stage: Phase 2
Modality: Small molecule
Target: EDNRA; 1
Indication: 1
Trial: 1
Developer

Indications

1

Type 1 diabetes mellitus with diabetic nephropathy
Phase 2, Not yet recruiting, NCT06072326, clinicaltrials.gov, 15 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Evidence for its targets1
Competitors4
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.